Search

everythinglearnresearchcommunity

for

Search:↓

Testosterone replacement therapy improved blood sugar and fat levels without raising prostate cancer risk in Japanese men with low testosterone.

Early hair loss may indicate future prostate issues.

Finasteride significantly reduces PSA levels in men, and doctors should adjust PSA readings for those taking the drug.

BMI is a simple, cost-effective tool for screening obesity and related diseases.

Low-dose finasteride and dutasteride reduce PSA levels by 27.8% in men with male androgenetic alopecia.

PSA could be a marker for hyperandrogenism in women, but more research is needed.

PSA might help diagnose PCOS and related skin issues, but more research is needed.

Finasteride can reduce prostate cancer risk but may delay diagnosis and cause sexual side effects.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

Hair loss is linked to higher prostate-specific antigen levels and urinary symptoms, likely due to age.

% free PSA and urinary markers help better identify prostate cancer.

Finasteride doesn't harm male fertility or sperm quality, but may slightly reduce ejaculate volume.

A genetic test can identify people at risk of male pattern baldness early, allowing for quicker treatment.

Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.

Metformin may lower PSA levels, possibly affecting prostate cancer development.

There's no link between hair loss type androgenic alopecia and benign prostatic hyperplasia, but early hair loss and family history can mean more severe alopecia.

Using a single PSA level to decide on a prostate biopsy is not effective; a more personalized approach considering various factors is recommended.

Drinking a lot of alcohol increases the risk of prostate cancer and can worsen the condition.

Gender-affirming hormone treatments need better patient-focused outcome measurements and standardized data collection.

Black ethnicity, prior PSA tests, enlarged prostate, and family history increase prostate cancer risk; Asian ethnicity, obesity, smoking, diabetes, and less sexual activity or no children decrease risk.

People with Down syndrome have a higher risk of skin disorders and need better screening and treatment.

Researchers created a simple tool to predict bladder blockage from prostate enlargement using urine flow rate and prostate volume.

Men with a certain baldness pattern at age 40-50 may have a higher risk of aggressive prostate cancer.

The care model improved timely diagnosis and treatment for psoriasis and psoriatic arthritis.

5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Men's age, urinary symptoms, and heart health risks create different types of erectile dysfunction.

Preventing cancer involves lifestyle changes, vaccinations, early screening, and understanding cancer's molecular basis.